These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 29482364)

  • 1. Efficacy and safety of the trastuzumab biosimilar candidate CT-P6.
    Esteva FJ; Saeki T; Kim H; Stebbing J
    Future Oncol; 2018 Aug; 14(19):1909-1919. PubMed ID: 29482364
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ABP 980: A Trastuzumab Biosimilar.
    Dhillon S
    BioDrugs; 2018 Oct; 32(5):511-514. PubMed ID: 30264234
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Trastuzumab Biosimilar (CT-P6) Compared With Reference Trastuzumab in Patients With HER2-positive Advanced Gastric Cancer: A Retrospective Analysis.
    Park JH; Yeo JH; Kim YS; Park I; Ahn HK; Cho EK; Shin DB; Yang JY; Kim HS; Lee WK; Sym SJ
    Am J Clin Oncol; 2022 Feb; 45(2):61-65. PubMed ID: 34991106
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical development of CT-P6 in HER2 positive breast cancer.
    Fu C; Stebbing J; Esteva FJ
    Expert Opin Biol Ther; 2019 Oct; 19(10):987-992. PubMed ID: 31507219
    [No Abstract]   [Full Text] [Related]  

  • 5. Budget Impact of Switching to Biosimilar Trastuzumab (CT-P6) for the Treatment of Breast Cancer and Gastric Cancer in 28 European Countries.
    Lee SM; Jung JH; Suh D; Jung YS; Yoo SL; Kim DW; Kim JA; Suh DC
    BioDrugs; 2019 Aug; 33(4):423-436. PubMed ID: 31201616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of biosimilar trastuzumab (CT-P6) in routine clinical practice in the Republic of Korea: a real-world post-marketing surveillance study.
    Park MH; Seo JH; Park JH; Seong MK; Park KU; Kim MK; Chang M; Koh SJ; Lee MH; Lim ST; Yoo YB; Oh SY; Kim SH; Ahn KY; Park TH; Ju H; Baek EH; Kim S; Kim N; Lee E; Kim TH
    Expert Opin Biol Ther; 2024 Apr; 24(4):305-312. PubMed ID: 38664937
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SB3 (Ontruzant
    Lamb YN
    BioDrugs; 2018 Jun; 32(3):293-296. PubMed ID: 29796993
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CT-P6 compared with reference trastuzumab for HER2-positive breast cancer: a randomised, double-blind, active-controlled, phase 3 equivalence trial.
    Stebbing J; Baranau Y; Baryash V; Manikhas A; Moiseyenko V; Dzagnidze G; Zhavrid E; Boliukh D; Stroyakovskii D; Pikiel J; Eniu A; Komov D; Morar-Bolba G; Li RK; Rusyn A; Lee SJ; Lee SY; Esteva FJ
    Lancet Oncol; 2017 Jul; 18(7):917-928. PubMed ID: 28592386
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of CT-P6 versus reference trastuzumab in HER2-positive early breast cancer: updated results of a randomised phase 3 trial.
    Esteva FJ; Baranau YV; Baryash V; Manikhas A; Moiseyenko V; Dzagnidze G; Zhavrid E; Boliukh D; Stroyakovskiy D; Pikiel J; Eniu AE; Li RK; Rusyn AV; Tiangco B; Lee SJ; Lee SY; Yu SY; Stebbing J
    Cancer Chemother Pharmacol; 2019 Oct; 84(4):839-847. PubMed ID: 31428820
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PF-05280014: A Trastuzumab Biosimilar.
    Paik J
    BioDrugs; 2018 Oct; 32(5):515-518. PubMed ID: 30280367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomised trial comparing the pharmacokinetics and safety of the biosimilar CT-P6 with reference trastuzumab.
    Esteva FJ; Stebbing J; Wood-Horrall RN; Winkle PJ; Lee SY; Lee SJ
    Cancer Chemother Pharmacol; 2018 Mar; 81(3):505-514. PubMed ID: 29330636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trastuzumab biosimilars vs trastuzumab originator in the treatment of HER2-positive breast cancer: a systematic review and network meta-analysis.
    Liu T; Liu D; Jin Y; Dong M
    Immunopharmacol Immunotoxicol; 2022 Dec; 44(6):809-815. PubMed ID: 35708278
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanism of action of the trastuzumab biosimilar CT-P6.
    Jeong SA; Choi JM; Park JM; Lee JY; Lee SJ; Lee SY; Lee SY; Park YA; Jeong HJ; Song YC; Kim SH; Chang SJ
    Expert Opin Biol Ther; 2019 Oct; 19(10):1085-1095. PubMed ID: 30541352
    [No Abstract]   [Full Text] [Related]  

  • 14. Totality of Scientific Evidence in the Development of ABP 980, a Biosimilar to Trastuzumab.
    Kolberg HC; Colleoni M; Santi P; Demetriou GS; Segui-Palmer MA; Fujiwara Y; Hurvitz SA; Hanes V
    Target Oncol; 2019 Dec; 14(6):647-656. PubMed ID: 31620980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ABP 980: promising trastuzumab biosimilar for HER2-positive breast cancer.
    Paplomata E; Nahta R
    Expert Opin Biol Ther; 2018 Mar; 18(3):335-341. PubMed ID: 29350568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Trastuzumab and its biosimilars].
    Sarosiek T; Morawski P
    Pol Merkur Lekarski; 2018 May; 44(263):253-257. PubMed ID: 29813044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of a Proposed Trastuzumab Biosimilar Compared With Trastuzumab on Overall Response Rate in Patients With ERBB2 (HER2)-Positive Metastatic Breast Cancer: A Randomized Clinical Trial.
    Rugo HS; Barve A; Waller CF; Hernandez-Bronchud M; Herson J; Yuan J; Sharma R; Baczkowski M; Kothekar M; Loganathan S; Manikhas A; Bondarenko I; Mukhametshina G; Nemsadze G; Parra JD; Abesamis-Tiambeng ML; Baramidze K; Akewanlop C; Vynnychenko I; Sriuranpong V; Mamillapalli G; Ray S; Yanez Ruiz EP; Pennella E;
    JAMA; 2017 Jan; 317(1):37-47. PubMed ID: 27918780
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of CT-P6 (trastuzumab biosimilar) versus reference trastuzumab in combination with pertuzumab in HER2-positive early-stage breast cancer: Preclinical and real-life clinical data.
    Bernat-Peguera A; Trigueros M; Ferrando-Díez A; Ibáñez C; Bystrup S; Martínez-Cardús A; Margelí M; Martínez-Balibrea E
    Breast; 2022 Apr; 62():1-9. PubMed ID: 35078146
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term efficacy and safety of CT-P6 versus trastuzumab in patients with HER2-positive early breast cancer: final results from a randomized phase III trial.
    Stebbing J; Baranau YV; Baryash V; Manikhas A; Moiseyenko V; Dzagnidze G; Zhavrid E; Boliukh D; Pikiel J; Eniu AE; Li RK; Tiangco B; Lee SJ; Kim S
    Breast Cancer Res Treat; 2021 Aug; 188(3):631-640. PubMed ID: 34148205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative Evaluation of Biosimilar Trastuzumab with Reference Trastuzumab Activity in HER2-Positive Breast Cancer Patients.
    AbdulHameed Saeed V; Mohammed NAK
    Arch Razi Inst; 2023 Jun; 78(3):981-988. PubMed ID: 38028843
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.